April 11, 2023
Patients have a preference for taking medicine orally, and tablets are the most commonly used form of solid oral medication. For many years, the pharmaceutical industry has been exploring ways to improve oral medications, intending to improve their safety and efficacy, leading to higher patient adherence.
Smartdose Technology is a novel innovation in tablet formulations by Akums Drugs and Pharmaceuticals Ltd that addresses some of the key challenges faced by patients when taking medication. By decreasing the size and weight of tablets, Smartdose Technology makes it easier for people, especially the elderly or those who have trouble swallowing large tablets, to take their medication. This is a novel solution that can improve medication compliance and overall health outcomes.
Smart Tablets over Conventional Oral Dosage
Oral medication administration is based on the idea that safe swallowing is a stable function in life and that swallowing tablets and capsules is a given competence of all humans over the age of 12. Dysphagia is a quiet and hidden issue that causes dehydration, malnutrition, and pneumonia in elderly persons.
Improve patient compliance by size reduction: Smartdose technology has the potential to significantly improve patient compliance. One of the main benefits of this technology is that it reduces the size and weight of tablets, making it easier for patients to swallow their medication by improving the overall experience of taking medication. This can lead to improved patient outcomes and increased confidence in their treatment.
Improve product characteristics: Smartdose technology has the potential to improve the properties of a medicine in a variety of ways, resulting in higher efficacy, increased patient compliance, and improved health outcomes for patients.
Reduced disintegration time: It is critical in the treatment of diseases such as hypertension to provide quick and constant medication administration to assist manage blood pressure levels. Telmisartan tablets manufactured with Akum’s smart-dose technology ensures the rapid breakdown of tablet and faster dissolution. This smart tablet has low sodium content and dissolves faster in the body, which improves medicine absorption and efficacy, resulting in improved blood pressure management.
Improved bioavailability: This innovative technology can increase the surface area-to-volume ratio, leading to improved solubility and bioavailability of the active ingredient. This enhances the rate and amount of dissolution, resulting in improved bioavailability as more of the active substance is absorbed by the body.
Excipients are ingredients included in drug formulations to improve their physical and chemical characteristics. Although these ingredients are usually considered to be safe and well-tolerated, some individuals may still experience adverse effects. For example, some people may develop an allergy to certain excipients. Others may experience digestive problems, particularly those with conditions like celiac disease or diabetes.
Reduced excipient load: Akum’s SmartDose Technology was used to reduce the excipient load by more than 60% in the 5mg Dapagliflozin tablet formulation and more than 80% in the 10 mg Dapagliflozin tablet formulation.
Akum’s Smartdose Technology is an effective technology for drugs with poor solubility, stability, and bioavailability. The size reduction technology is an efficient means of enhancing the bioavailability of poorly soluble medications without changing their chemical makeup.
To accomplish the intended effect, the medicine should be delivered to its site of action at a pace and concentration that maximizes therapeutic impact while minimizing side effects. Much attention must be paid to the area of building medication delivery systems with organoleptic elegance and optimum patient compliance. In the next few years, emerging nations such as India are projected to see a greater prevalence of patient-centric research and healthcare systems.
Akums Drugs and Pharmaceuticals believes that paying more attention to dosage size reduction during the development and manufacturing of solid oral dosage forms will become standard practice, and drug product presentations in the form of multi-particulate systems or small tablets will become more common in the coming years.
Satwinder Singh is an Independent Director of our Company. He holds a bachelor’s degree in commerce and a bachelor’s degree in law from Guru Nanak Dev University, Punjab. He is a fellow member of the Institute of Company Secretaries of India (‘ICSI’).
He was the past Chairman of Expert Group on Secretarial Standards and Secretarial Standards Committee for the years 2021 and 2022. He has also held the chairmanship of the Secretarial Standards Board for the years 2019 and 2020. He was also the Chairman of the Task Force on NCLT/NCLAT for the year 2023.
Sanjay Sinha is a Whole Time Director of our Company. He holds a bachelor’s degree in pharmaceutical sciences from Ranchi University and a master’s degree in pharmacy from the University of Delhi. He was previously associated with Ipca Laboratories Limited and Famy Care Limited.
He joined our Company with effect from November 26, 2022 as President of Operations.
Ms. Gowrishankar comes with a wide range of experience across different domains.
Besides Akums, she is currently an independent director on the boards of several prominent companies including Cyient, Gabriel India, Greenlam Industries, Arohan Financial Services, Ashv Finance, Intellecap Advisory Services, Altum Credo Home Finance and Premium Transmission.
In the past, Ms. Gowrishankar has served on the boards of BP India Services, the holding company of oil and gas major BP in India, and subsidiaries of Cummins India.
Not only has she led teams both in India and outside, she has also been an executive coach to the top leadership at BP plc and other companies.
Ms. Gowrishankar has been a strategic human resources advisor to companies like Safari Industries, FlyNava Technologies, Quantum Consumer Solutions, BP Global Solutions India and Cornerstone India, to name a few. She was also heading the group HR council for the Aavishkaar Group.
She holds a postgraduate degree in personnel management and industrial relations from the prestigious XLRI, Jamshedpur, and a bachelor of arts in sociology from Stella Maris College, Chennai.
A former career bureaucrat, Mr. Kalra spent 36 years in the elite Indian Revenue Service (IRS), and held various important positions. He now heads the audit committee of the company, as its chairman.
From 2005-12, Mr. Kalra was a member of the Income Tax Appellate Tribunal, where he delivered several landmark judgements. Before that, Mr. Kalra served as the assistant commissioner, deputy commissioner, joint commissioner and additional commissioner in the income tax department and has served across the country.
Mr. Kalra, who has worked actively to extend financial help to underprivileged children, has an excellent academic record. He earned a Bachelor of Science degree from Kurukshetra University with a gold medal. He holds a masters in science from Panjab University and a law degree from Jodhpur University.
Mr. Handa is a veteran of the pharmaceutical industry in India. He headed Pfizer India as managing director and country manager from 2005 to 2012. Before Pfizer, he was also the managing director at Wyeth Ltd.
After leaving Pfizer, Mr Handa joined Samarth Life Sciences as President. He went on to serve as the non-executive chairman on the board of Union Bank of India, one of the most prominent government-owned lenders. Mr. Handa recently also joined the board of merchant payments firm BharatPe as an independent director.
Mr. Handa has diverse experience in finance, commercial, strategy, business development, M&A, banking, corporate affairs. He is also experienced across sectors like engineering and consumer in companies
like Schrader Scovill, Hindustan Unilever Limited, and State Industrial Investment Corporation of Maharashtra. Mr. Handa has wide experience in markets like the US, Southeast Asia, Africa, Bangladesh, and Sri Lanka.
One of Mr. Handa’s key focus areas is building a diverse organisation. He has driven various teams to hire and retain women colleagues in management and most importantly in sales positions – an initiative unheard of in the Indian pharmaceutical industry. He has managed this by sensitization and by developing women-friendly policies. These initiatives are now case studies and were showcased at a ministerial roundtable held in Turkey.
Mr. Handa is a qualified management accountant and company secretary, and has a master’s degree in commerce
Sunil Kumar Thakur is a Non-Executive Director of our Company and is a nominee of Ruby QC Investment Holdings Pte. Ltd. on our Board. He holds a bachelor’s degree in business administration from Thames Valley University and a master’s degree in international business from the University of Delhi.
He is currently associated with Quadria Capital Advisors Private Limited as a partner, where he leads the investments, portfolio management and divestment activities across South-Asia and also serves on the investment committee of the Quadria Capital Fund II GP.
Mr. Rathore is a three-decade old veteran of the pharmaceutical industry. He is an accomplished, outcome-driven executive with a proven track record in leading challenging initiatives, with emphasis on strategic planning, manufacturing, engineering, quality assurance, project development, budget management and human resources.
Mr. Rathore has, over the years, shown tremendous leadership ability and has extensive experience in managing pharmaceutical plants as per international standards.
Mr. Rathore holds a master’s degree in pharmacy and a postgraduate diploma in management from Rajasthan University.Before Akums, Mr. Rathore worked with companies like Bal Pharma, Tirupati Zion Medicare, Micro Labs, Scott-Edil Pharmacia, Nicholas Piramal, Lupin and Torrent Pharma.
Mr. Sandeep Jain has been the force behind setting up Akums’ state-of-the-art world-class facilities. He has had a key role in making contract manufacturing the most viable industry model.
He has been associated with several leading trade and industry bodies and has advocated the cause of the Indian pharmaceutical sector. In 2013-14, he was the president of the Uttarakhand state council of the Confederation of Indian Industry (CII). The same year, he also headed the state’s Association of Pharmaceutical
He has also served as the chairman of the Chamber of Commerce and Industry, Uttarakhand and has been a member of the managing committee of the PHD Chamber of Commerce and Industry and the vice-chairman of the Foundation of Pharma Entrepreneurs (FOPE)
Mr. Sanjeev Jain was the principal force behind founding Akums, and ranks among the pioneers of the Indian pharma sector. Mr. Jain is known as a visionary leader and mentor. He has been guiding not just Akums but the industry as a whole to greater heights over the last decade and a half.
A people person, he has more than three decades of experience in the field of pharmaceuticals sales and marketing. He has received multiple industry awards, including the prestigious Dynamic Entrepreneur Award at the 6th Annual Pharmaceutical Leadership Summit & Business Leadership Awards in 2014.
Under his leadership, Akums has made several national and foreign collaborations. His innovative ideas in product development, patents, and customer retention have helped the company chart new growth paths over the year